Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response Markers.

IF 4.5 2区 医学 Q1 CLINICAL NEUROLOGY
Priyanka Singh, Ankit Srivastava, Debleena Guin, Sarita Thakran, Jyoti Yadav, Puneet Chandna, Mamta Sood, Rakesh Kumar Chadda, Ritushree Kukreti
{"title":"Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response Markers.","authors":"Priyanka Singh,&nbsp;Ankit Srivastava,&nbsp;Debleena Guin,&nbsp;Sarita Thakran,&nbsp;Jyoti Yadav,&nbsp;Puneet Chandna,&nbsp;Mamta Sood,&nbsp;Rakesh Kumar Chadda,&nbsp;Ritushree Kukreti","doi":"10.1093/ijnp/pyad001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The clinical heterogeneity in major depressive disorder (MDD), variable treatment response, and conflicting findings limit the ability of genomics toward the discovery of evidence-based diagnosis and treatment regimen. This study attempts to curate all genetic association findings to evaluate potential variants for clinical translation.</p><p><strong>Methods: </strong>We systematically reviewed all candidates and genome-wide association studies for both MDD susceptibility and antidepressant response, independently, using MEDLINE, particularly to identify replicated findings. These variants were evaluated for functional consequences using different in silico tools and further estimated their diagnostic predictability by calculating positive predictive values.</p><p><strong>Results: </strong>A total of 217 significantly associated studies comprising 1200 variants across 545 genes and 128 studies including 921 variants across 412 genes were included with MDD susceptibility and antidepressant response, respectively. Although the majority of associations were confirmed by a single study, we identified 31 and 18 replicated variants (in at least 2 studies) for MDD and antidepressant response. Functional annotation of these 31 variants predicted 20% coding variants as deleterious/damaging and 80.6% variants with regulatory effect. Similarly, the response-related 18 variants revealed 25% coding variant as damaging and 88.2% with substantial regulatory potential. Finally, we could calculate the diagnostic predictability of 19 and 5 variants whose positive predictive values ranges from 0.49 to 0.66 for MDD and 0.36 to 0.66 for response.</p><p><strong>Conclusions: </strong>The replicated variants presented in our data are promising for disease diagnosis and improved response outcomes. Although these quantitative assessment measures are solely directive of available observational evidence, robust homogenous validation studies are required to strengthen these variants for molecular diagnostic application.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":"692-738"},"PeriodicalIF":4.5000,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586057/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ijnp/pyad001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The clinical heterogeneity in major depressive disorder (MDD), variable treatment response, and conflicting findings limit the ability of genomics toward the discovery of evidence-based diagnosis and treatment regimen. This study attempts to curate all genetic association findings to evaluate potential variants for clinical translation.

Methods: We systematically reviewed all candidates and genome-wide association studies for both MDD susceptibility and antidepressant response, independently, using MEDLINE, particularly to identify replicated findings. These variants were evaluated for functional consequences using different in silico tools and further estimated their diagnostic predictability by calculating positive predictive values.

Results: A total of 217 significantly associated studies comprising 1200 variants across 545 genes and 128 studies including 921 variants across 412 genes were included with MDD susceptibility and antidepressant response, respectively. Although the majority of associations were confirmed by a single study, we identified 31 and 18 replicated variants (in at least 2 studies) for MDD and antidepressant response. Functional annotation of these 31 variants predicted 20% coding variants as deleterious/damaging and 80.6% variants with regulatory effect. Similarly, the response-related 18 variants revealed 25% coding variant as damaging and 88.2% with substantial regulatory potential. Finally, we could calculate the diagnostic predictability of 19 and 5 variants whose positive predictive values ranges from 0.49 to 0.66 for MDD and 0.36 to 0.66 for response.

Conclusions: The replicated variants presented in our data are promising for disease diagnosis and improved response outcomes. Although these quantitative assessment measures are solely directive of available observational evidence, robust homogenous validation studies are required to strengthen these variants for molecular diagnostic application.

主要抑郁症的遗传景观:潜在的诊断和抗抑郁反应标志物的评估。
背景:严重抑郁障碍(MDD)的临床异质性、可变的治疗反应和相互矛盾的发现限制了基因组学发现循证诊断和治疗方案的能力。这项研究试图整理所有的基因关联发现,以评估临床翻译的潜在变体。方法:我们使用MEDLINE系统地回顾了MDD易感性和抗抑郁反应的所有候选和全基因组关联研究,特别是为了确定重复的发现。使用不同的计算机工具评估这些变体的功能后果,并通过计算阳性预测值进一步估计其诊断可预测性。结果:共有217项显著相关的研究,包括545个基因的1200个变体,以及128项研究,包括412个基因的921个变体,分别与MDD易感性和抗抑郁反应有关。尽管大多数关联都通过一项研究得到了证实,但我们(在至少2项研究中)确定了31和18种MDD和抗抑郁反应的重复变体。对这31个变体的功能注释预测,20%的编码变体是有害/破坏性的,80.6%的变体具有调节作用。同样,与反应相关的18种变体显示,25%的编码变体具有破坏性,88.2%具有显著的调节潜力。最后,我们可以计算19个和5个变体的诊断可预测性,它们的阳性预测值范围为MDD的0.49至0.66,反应的0.36至0.66。结论:在我们的数据中呈现的复制变异对疾病诊断和改善反应结果是有希望的。尽管这些定量评估措施只是对现有观察证据的指导,但需要强有力的同质验证研究来加强这些变体的分子诊断应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.10%
发文量
230
审稿时长
4-8 weeks
期刊介绍: The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信